MSD Partners with Owkin to Develop MSI-H Biomarker Screening for Cancers

US pharmaceutical company Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a partnership with French firm Owkin to develop and commercialize a pre-screening procedure for identifying the microsatellite instability- (MSI) H biomarker in various cancers. The initiative aims to test for MSI-H in endometrial, gastric, small intestinal, and biliary cancers to determine patients who could potentially benefit from immune checkpoint inhibitor (ICI) therapy. The project, initially focused in the European Union (EU), will also broaden the application of Owkin’s AI-powered MSI digital pathology diagnostic, which is currently used in colorectal cancer.- Flcube.com